{  
   "ProductFound":"4 Products Found",
   "ProductListing":[  
      {  
         "ShowMoreText":"Show More",
         "ShowLessText":"Show Less",
         "ProductTitle":" From: ",
         "FromText":null,
         "Results":[  
            {  
               "SectorTags":[  
                  "Business Portfolio Strategy",
                  "Competitive and Market intelligence"
               ],
               "SubSectorTags":null,
               "Category":"SampleContent",
               "SectorsComputed":[  
                  "3ec6ceae0de94903a3acda6ae1d87534",
                  "993afb82f62a4e359937915b67fd0e21"
               ],
               "SubSectorsComputed":[  
                  "317fe06572a84108b89b37731b8f3a4d",
                  "7e3b45f29e7145cfaaee26991dfe5c7c",
                  "21cc811a235d40a990995faa8ee1c090"
               ],
               "Title":"Zurampic Clinical Development Timeline",
               "Description":"Chronicle of the development and review of Ardea's (now Ironwood's) lesinurad",
               "ShortDescription":null,
               "PageURL":"/en-US/sitecore/content/InformaShopWindow/Pharma/Site Data/Resources/Sample Insights/zurampicclinicaldevelopmenttimeline",
               "Image":"",
               "Benefits":null,
               "CtaTypeName":"",
               "CtaText":"",
               "FreeTrialLink":null,
               "DetailText":"Details",
               "SectorType":null,
               "Product":"commercial",
               "ContentType":"News Headline",
               "Profile":"Tore p M Alden",
               "PublicationDate":"15.08.2016",
               "Topic":[  
                  "deal-trends:9f86725e2e9d4e3f9835b1129a04f26b",
                  "Vaccines:35f7ca223645492d85f218565cae440a",
                  "Orphan diseases:7bd30967a89f4a91bd3febcd09788a85"
               ],
               "VideoImage":null,
               "GeneralLink":null,
               "Link":null,
               "LinkText":"View News Headline",
               "ByKeyword":null,
               "TopicKeyword":null,
               "Video":null,
               "BrandType":null,
               "Price":"200",
               "ELink":null,
               "ECommerceLink":null,
               "TopicURLS":null,
               "FormType":null,
               "Id":"c7118e1cca6743428b0d3f623c6b1392"
            },
            {  
               "SectorTags":[  
                  "Business Portfolio Strategy",
                  "Competitive and Market intelligence"
               ],
               "SubSectorTags":null,
               "Category":"SampleContent",
               "SectorsComputed":[  
                  "3ec6ceae0de94903a3acda6ae1d87534",
                  "993afb82f62a4e359937915b67fd0e21"
               ],
               "SubSectorsComputed":[  
                  "317fe06572a84108b89b37731b8f3a4d",
                  "7e3b45f29e7145cfaaee26991dfe5c7c",
                  "21cc811a235d40a990995faa8ee1c090"
               ],
               "Title":"Zurampic Reviewers",
               "Description":"FDA staff who participated in the review of the URAT1 inhibitor for treatment of hyperuricemia associated with gout.",
               "ShortDescription":null,
               "PageURL":"/en-US/sitecore/shell/InformaShopWindow/Pharma/Site Data/Resources/Sample Insights/zurampicreviewers",
               "Image":"",
               "Benefits":null,
               "CtaTypeName":"",
               "CtaText":"",
               "FreeTrialLink":null,
               "DetailText":"Details",
               "SectorType":null,
               "Product":"commercial",
               "ContentType":"News Headline",
               "Profile":"Tore p M Alden",
               "PublicationDate":"15.08.2016",
               "Topic":[  
                  "Vaccines:35f7ca223645492d85f218565cae440a",
                  "Orphan diseases:7bd30967a89f4a91bd3febcd09788a85"
               ],
               "VideoImage":null,
               "GeneralLink":null,
               "Link":null,
               "LinkText":"View News Headline",
               "ByKeyword":null,
               "TopicKeyword":null,
               "Video":null,
               "BrandType":null,
               "Price":"200",
               "ELink":null,
               "ECommerceLink":null,
               "TopicURLS":null,
               "FormType":null,
               "Id":"6e0ecbc582dd483d847c68a799041610"
            },
            {  
               "SectorTags":[  
                  "Business Portfolio Strategy",
                  "Competitive and Market intelligence"
               ],
               "SubSectorTags":null,
               "Category":"SampleContent",
               "SectorsComputed":[  
                  "3ec6ceae0de94903a3acda6ae1d87534",
                  "993afb82f62a4e359937915b67fd0e21"
               ],
               "SubSectorsComputed":[  
                  "317fe06572a84108b89b37731b8f3a4d",
                  "7e3b45f29e7145cfaaee26991dfe5c7c",
                  "21cc811a235d40a990995faa8ee1c090"
               ],
               "Title":"Zimmer Biomet Rolls Out Comprehensive Episode-Of-Care Program",
               "Description":"The orthopedics giant is integrating a suite of products and services to help hospitals transition to value-based health-care payment models...",
               "ShortDescription":null,
               "PageURL":"/en-US/sitecore/shell/InformaShopWindow/Pharma/Site Data/Resources/Sample Insights/zimmerbiometrollsoutcomprehensiveepisodeofcareprogram",
               "Image":"",
               "Benefits":null,
               "CtaTypeName":"",
               "CtaText":"",
               "FreeTrialLink":null,
               "DetailText":"Details",
               "SectorType":null,
               "Product":"commercial",
               "ContentType":"News Headline",
               "Profile":"Eric M Allan",
               "PublicationDate":"12.08.2016",
               "Topic":[  
                  "Vaccines:35f7ca223645492d85f218565cae440a",
                  "Orphan diseases:7bd30967a89f4a91bd3febcd09788a85",
                  "Reimbursement:feb5ed1f99c2428e9bbe373227d1372e"
               ],
               "VideoImage":null,
               "GeneralLink":null,
               "Link":null,
               "LinkText":"View News Headline",
               "ByKeyword":null,
               "TopicKeyword":null,
               "Video":null,
               "BrandType":null,
               "Price":"200",
               "ELink":null,
               "ECommerceLink":null,
               "TopicURLS":null,
               "FormType":null,
               "Id":"2d51fedfa9004656b4cbc5991ed60028"
            },
            {  
               "SectorTags":[  
                  "Business Portfolio Strategy",
                  "Competitive and Market intelligence"
               ],
               "SubSectorTags":null,
               "Category":"SampleContent",
               "SectorsComputed":[  
                  "3ec6ceae0de94903a3acda6ae1d87534",
                  "993afb82f62a4e359937915b67fd0e21"
               ],
               "SubSectorsComputed":[  
                  "317fe06572a84108b89b37731b8f3a4d",
                  "7e3b45f29e7145cfaaee26991dfe5c7c",
                  "21cc811a235d40a990995faa8ee1c090"
               ],
               "Title":"Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged",
               "Description":"Australia's new policy of 'a'-flagging biosimilars, or allowing them to be substituted for the prescribed originator drug in the pharmacy...",
               "ShortDescription":null,
               "PageURL":"/en-US/sitecore/content/InformaShopWindow/Pharma/Site Data/Resources/Sample Insights/australiasbiosimilarsubstitutionpolicyunderfireasetanerceptproductisaflagged",
               "Image":"",
               "Benefits":null,
               "CtaTypeName":"",
               "CtaText":"",
               "FreeTrialLink":null,
               "DetailText":"Details",
               "SectorType":null,
               "Product":"commercial",
               "ContentType":"News Headline",
               "Profile":"Ian  somerhalder",
               "PublicationDate":"22.08.2016",
               "Topic":[  
                  "cell-and-gene-therapy:fe1fff99e34742a4aaa8f9d26406c63c",
                  "clinical-trial-optimization:a20cf3657f724ec28af306084159e58c",
                  "Orphan diseases:7bd30967a89f4a91bd3febcd09788a85"
               ],
               "VideoImage":null,
               "GeneralLink":null,
               "Link":null,
               "LinkText":"View News Headline",
               "ByKeyword":null,
               "TopicKeyword":null,
               "Video":null,
               "BrandType":null,
               "Price":"200",
               "ELink":null,
               "ECommerceLink":null,
               "TopicURLS":null,
               "FormType":null,
               "Id":"0395d2cc0a204142a063ff900121292b"
            }
         ]
      }
   ],
   "FacetSections":null,
   "SiteFacets":{  
      "InformationType":[  

      ],
      "Role":[  

      ],
      "Product":[  
         {  
            "Key":"commercial",
            "Value":"d88f8d2da7294b89949ad8fcf6cc97aa"
         }
      ],
      "Sector":[  
         {  
            "Key":"Business Portfolio Strategy",
            "Value":"3EC6CEAE-0DE9-4903-A3AC-DA6AE1D87534"
         },
         {  
            "Key":"Competitive and Market intelligence",
            "Value":"993AFB82-F62A-4E35-9937-915B67FD0E21"
         }
      ],
      "SubSector":[  
         {  
            "Key":"Clinical Trials",
            "Value":"317FE065-72A8-4108-B89B-37731B8F3A4D"
         },
         {  
            "Key":"Deals & Financing",
            "Value":"21CC811A-235D-40A9-9099-5FAA8EE1C090"
         },
         {  
            "Key":"Epidemiology",
            "Value":"7E3B45F2-9E71-45CF-AAEE-26991DFE5C7C"
         }
      ],
      "SubSubSector":[  
         {  
            "Key":"Company profile",
            "Value":"FBDB4747-2FA1-4CDA-8638-EF6B4FE5F601"
         },
         {  
            "Key":"Drug Deliver",
            "Value":"1C43D457-6910-4D11-9BD8-4347332A53DF"
         },
         {  
            "Key":"Cardiovascular",
            "Value":"1018AA85-0D92-4B04-A008-8A99225C63BD"
         },
         {  
            "Key":"In Vitro Diagnostics",
            "Value":"A40E877D-17E9-4582-97E6-ECD186737781"
         },
         {  
            "Key":"Metabolic",
            "Value":"F5D8B6EB-DC56-4279-A12E-23750CFA49C8"
         },
         {  
            "Key":"Orthopedics",
            "Value":"EF3FE9ED-9D28-4C06-BE98-E3A905AF93B3"
         }
      ],
      "ProductType":[  

      ],
      "ContentType":[  
         {  
            "Key":"News Headline",
            "Value":"99a0959392e647f88ee7fe2a6588a693"
         }
      ],
      "Specialist":[  
         {  
            "Key":"Tore p M Alden",
            "Value":"be0c3eae3e1f41de87348214ff6f302a"
         },
         {  
            "Key":"Eric M Allan",
            "Value":"1ab0328bb505495b88da0acc6338af48"
         },
         {  
            "Key":"Ian  somerhalder",
            "Value":"65e60ff0f4a142c58785ffe546459f07"
         }
      ]
   }
}
